tebipenem pivoxil hydrobromide + omeprazole

This combination, tebipenem pivoxil hydrobromide + omeprazole, is an oral regimen pairing a novel oral carbapenem prodrug—**tebipenem pivoxil hydrobromide**—with **omeprazole**, a proton pump inhibitor. Tebipenem pivoxil hydrobromide rapidly converts in vivo to tebipenem, which inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, exhibiting broad-spectrum activity against Gram-positive and Gram-negative bacteria, including resistant pathogens such as ESBL-producing and fluoroquinolone-resistant Enterobacterales[2][3][6]. Omeprazole suppresses gastric acid secretion via proton pump inhibition in gastric parietal cells[2]. The combination may be studied to understand pharmacokinetics and drug-drug interaction, as omeprazole can modestly lower peak plasma levels (Cmax) of tebipenem but does not impact its overall antimicrobial efficacy (AUC is pharmacodynamic driver for tebipenem)[1][2][3].

Other names

tebipenem HBr + omeprazoleTBP + omeprazole